English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Two rotavirus vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline) have been developed to neutralize the most common rotavirus serotypes, and are now available in the global market. These vaccines are primarily aimed at reducing rotavirus gastroenteritis in children in the least developed countries, where rotavirus mortality rate is believed to be greatest. Thus, the World Health Organization (WHO) has recommended rotavirus vaccination be included in all national immunization programs, while the least developed countries have so far not come up with clear vision and long term strategy on vaccine implementation, and several questions, in addition to this, remain unanswered.

Rotavirus, Vaccine and Unanswered Questions: A Perspective from a Least Developed Country